SCHEDULE: Citadel Discloses 5.0% Stake in Pliant Therapeutics

Citadel and its affiliates, including Kenneth Griffin, have disclosed a 5.0% beneficial ownership stake in Pliant Therapeutics, Inc. through a Schedule 13G filing.

Summary

• Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing reports beneficial ownership of common stock in PLIANT THERAPEUTICS, INC. (CUSIP: 729139105).
• Kenneth Griffin, through his various entities, beneficially owns an aggregate of 3,042,133 shares, representing 5.0% of the outstanding common stock.
• Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each beneficially own 2,099,798 shares, representing 3.4% of the outstanding common stock.
• Citadel Securities LLC beneficially owns 913,609 shares, representing 1.5% of the outstanding common stock.
• Citadel Securities Group LP and Citadel Securities GP LLC each beneficially own 942,335 shares, representing 1.5% of the outstanding common stock.
• All reported shares are held with shared voting and shared dispositive power among the respective reporting persons.
• The percentages are based on 61,449,385 shares outstanding as of November 1, 2025, as reported in the issuer's Form 10-Q filed on November 6, 2025.
• The securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial stake by a major investment firm like Citadel can indicate confidence in Pliant Therapeutics' long-term prospects and potentially attract further institutional interest.

Positives

• A significant investment firm like Citadel taking a 5.0% stake can be seen as a vote of confidence in Pliant Therapeutics' future prospects.
• The passive nature of the investment (Rule 13d-1(c) filing) suggests a long-term investment perspective rather than an activist intent.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Pliant Therapeutics' future outlook, as it is solely a disclosure of beneficial ownership.

Management Comments

• The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a prominent hedge fund like Citadel in a biotechnology company such as Pliant Therapeutics often signals institutional interest in the sector or the specific company's pipeline. While this is a passive investment, it could draw increased attention from other institutional investors and analysts to Pliant Therapeutics, which operates in the competitive and innovation-driven biopharmaceutical industry.

Comparison to Industry Standards

• StockSavvy.ai observes that a 5.0% stake by a major investment firm like Citadel is a notable position, often indicating a belief in the long-term value or strategic potential of the company.
• While direct comparisons to specific projects or results are not applicable for an ownership disclosure, such an investment by a firm known for its rigorous analysis, similar to how other large funds like BlackRock or Vanguard might build positions in promising biotech firms, suggests a positive assessment of Pliant Therapeutics' fundamentals or market opportunity.
• This level of institutional backing can be a positive signal, aligning with broader trends of capital flowing into innovative life sciences companies.

Stakeholder Impact

• Shareholders: May view the investment by Citadel as a positive endorsement, potentially leading to increased investor confidence and demand for shares.
• Management: Could feel increased scrutiny or validation from a prominent institutional investor holding a significant stake.
• Competitors: May observe the investment as a signal of Pliant Therapeutics' perceived value or potential in the market.

Key Dates

Recommendation

While the disclosure of a significant stake by Citadel is a positive signal, this filing primarily provides ownership information rather than new operational or financial performance data. A 'hold' recommendation is appropriate as it acknowledges the positive institutional interest without suggesting immediate action based solely on this ownership update, pending further fundamental analysis of Pliant Therapeutics' business and financial performance.

Keywords

Pliant Therapeutics, Citadel, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Institutional Investment, Biotechnology, Healthcare, Stock Ownership, SEC Filing